Authors : Nitin Patiyal, Nitin Patiyal, Amit Bhardwaj, Amit Bhardwaj, Dinesh Kansal, Dinesh Kansal, Atal Sood, Atal Sood
DOI : 10.18231/j.ijcaap.2021.007
Volume : 6
Issue : 1
Year : 2021
Page No : 37-39
A case of central hypothyroidism, following controlled-release carbamazepine (CBZ-CR) monotherapy for focal seizure prophylaxis. A 19 years old woman, presented to the neurology department with history of three episodes of sudden onset, abnormal body movements during sleep. Patient was diagnosed as a case of focal seizures with secondary generalization and was prescribed tablet CBZ-CR 300 mg twice a day for seizure prophylaxis. 3 months later patient presented with complaints of facial hair growth and menstrual irregularities. The patient was seizure free and was continuing with the treatment. Blood biochemistry parameters indicated central hypothyroidism. According toWorld Health Organization Uppsala monitoring
Centre (WHO-UMC) causality assessment, she was classified as ‘possible’ for carbamazepine-induced central hypothyroidism. Carbamazepine was discontinued. She was switched to tablet levetiracetam 500 mg twice daily, thyroxine 25 microgram once daily and clobazam 10 mg at bedtime.
Conclusion: Thyroid function tests should be monitored in patients receiving carbamazepine therapy.
Keywords: Carbamazepine, Drug induced hypothyroidism, Focal seizure, Thyroid function tests, Porencephaly.